Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06490055 · ClinicalTrials.gov registry record
Predicting the Efficacy in Advanced Gastric Cancer.
A clinical trial, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- 162
- Enrollment target
NCT06490055 is a clinical trial that has completed, run by City of Hope Medical Center. The registered enrollment target is 162 participants.
The verdict
NCT06490055 has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- 162 participants
- Enrollment target
Study Summary
With advances in chemotherapy for gastric cancer, it is important to identify patients who will respond effectively to specific therapies. This longitudinal study aimed to establish a liquid-biopsy assay that can predict response to ramucirumab plus paclitaxel therapy in patients with advanced gastric cancer.
Interventions
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2025-07-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06490055
The ClinicalTrials.gov registry entry for NCT06490055 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paclitaxel is the first listed.
NCT06490055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06490055 about?
NCT06490055 is a clinical study titled "Predicting the Efficacy in Advanced Gastric Cancer.". With advances in chemotherapy for gastric cancer, it is important to identify patients who will respond effectively to specific therapies. This longitudinal study aimed to establish a liquid-biopsy assay that can predict response to ramucirumab plus paclitaxel therapy in patients with advanced gastr...
What is the current status of trial NCT06490055?
This trial is currently completed. The enrollment target is 162 participants. The study started on 2018-10-01. Estimated completion is 2025-07-01.
What interventions are being tested in trial NCT06490055?
The interventions under investigation include: Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT06490055?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.